News and Announcements
Sequoia Capital backed Incomlend completes over USD 400 million in trade receivable transactions
- Published January 03, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Incomlend provides credit-insured, short-term credit opportunities of 5-7% p.a. in USD.
Incomlend is an award-winning global trade finance fintech-platform merging cross-border factoring and supply chain finance solutions to companies worldwide with insured, uncorrelated private credit opportunities for accredited investors and has financed over USD 400 million of receivables since inception in 2016.
In 2019, Incomlend announced a major partnership with CMA CGM Group on SHIPFIN Trade Finance, an Incomlend-developed solution exclusively for CMA CGM to deliver trade finance services, to its clients. In 2020, Incomlend was awarded the Best Fintech Startup at the GTR Leaders in Trade Award. Incomlend also closed a USD 20 million Series A round led by Sequoia Capital India and CMA CGM Group, that will allow the firm to continue advancing their capabilities in digital invoice finance underwriting and processing.
Accredited investors can access the fast growing and booming SME segment across multiple sectors in South East Asia, Europe, and America through Incomlend by participating either directly on the Incomlend platform, where investors can pick and choose their short-term insured private credit opportunity and potentially earn uncorrelated yield of 5-7%, or through a dedicated Luxembourg based Reserved Alternative Investment Fund managed by an independent Alternative Asset Manager that has historically yielded 5-7%.
To get started, simply reach out to us at [email protected]
About Incomlend
Incomlend works as a marketplace, where SME businesses can optimize their working capital by tapping into a pool of accredited Investors comprising of High Net-worth Individuals, Family Offices, Funds and Institutional Investors . Incomlend has financed over 400MM USD of receivable since inception in 2016 and in 2019 alone Incomlend financed 250MM of invoices.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
